Zhifa Zhang1, Xiaofeng Dai2,3, Xiao Chen4, Jianying Zhang5. 1. Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China. 2. Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China. 1281423490@qq.com. 3. Wuhan Ammunition Life-tech Company, Ltd., Wuhan, 430200, Hubei, China. 1281423490@qq.com. 4. School of Biotechnology, Jiangnan University, Wuxi, 214122, China. 5. Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, 450001, China.
Abstract
BACKGROUND: Breast carcinomas are heterogeneous diseases with distinct clinical outcomes and cancer stem cell (CSC) percentages. Exploring breast carcinoma stem cell landscape could help understand the heterogeneity of such cancers with profound clinical relevance. METHODS: We conducted transcriptional profiling of CSCs and non-stem cancer cells isolated from three triple-negative breast carcinoma cell lines, analyzed the CSC transcriptome landscape that drives breast carcinoma heterogeneity through differentially expressed gene identification, gene ontology (GO) and pathway enrichment analyses as well as network construction, and experimentally validated the network hub gene. RESULTS: We identified a CSC feature panel consisting of 122 and 381 over-represented and under-expressed genes capable of differentiating breast carcinoma subtypes. We also underpinned the prominent roles of the PI3K-AKT pathway in empowering carcinoma cells with uncontrolled proliferative and migrative abilities that ultimately foster cancer stemness, and revealed the potential promotive roles of ATP6V1B1 on breast carcinoma stemness through functional in vitro studies. CONCLUSIONS: Our study contributes in identifying a CSC feature panel for breast carcinomas that drives breast carcinoma heterogeneity at the transcriptional level, which provides a reservoir for diagnostic marker and/or therapeutic target identification once experimentally validated as demonstrated by ATP6V1B1.
BACKGROUND:Breast carcinomas are heterogeneous diseases with distinct clinical outcomes and cancer stem cell (CSC) percentages. Exploring breast carcinoma stem cell landscape could help understand the heterogeneity of such cancers with profound clinical relevance. METHODS: We conducted transcriptional profiling of CSCs and non-stem cancer cells isolated from three triple-negative breast carcinoma cell lines, analyzed the CSC transcriptome landscape that drives breast carcinoma heterogeneity through differentially expressed gene identification, gene ontology (GO) and pathway enrichment analyses as well as network construction, and experimentally validated the network hub gene. RESULTS: We identified a CSC feature panel consisting of 122 and 381 over-represented and under-expressed genes capable of differentiating breast carcinoma subtypes. We also underpinned the prominent roles of the PI3K-AKT pathway in empowering carcinoma cells with uncontrolled proliferative and migrative abilities that ultimately foster cancer stemness, and revealed the potential promotive roles of ATP6V1B1 on breast carcinoma stemness through functional in vitro studies. CONCLUSIONS: Our study contributes in identifying a CSC feature panel for breast carcinomas that drives breast carcinoma heterogeneity at the transcriptional level, which provides a reservoir for diagnostic marker and/or therapeutic target identification once experimentally validated as demonstrated by ATP6V1B1.
Entities:
Keywords:
Biomarker; Breast carcinoma; Cancer stem cell; Transcriptome
Authors: Liangliang Shen; John M O'Shea; Mohan R Kaadige; Stéphanie Cunha; Blake R Wilde; Adam L Cohen; Alana L Welm; Donald E Ayer Journal: Proc Natl Acad Sci U S A Date: 2015-04-13 Impact factor: 11.205
Authors: Jonas Bergh; Igor M Bondarenko; Mikhail R Lichinitser; Annelie Liljegren; Richard Greil; Nataliya L Voytko; Anatoly N Makhson; Javier Cortes; Alain Lortholary; Joachim Bischoff; Arlene Chan; Suzette Delaloge; Xin Huang; Kenneth A Kern; Carla Giorgetti Journal: J Clin Oncol Date: 2012-02-13 Impact factor: 44.544
Authors: Matthew D Burstein; Anna Tsimelzon; Graham M Poage; Kyle R Covington; Alejandro Contreras; Suzanne A W Fuqua; Michelle I Savage; C Kent Osborne; Susan G Hilsenbeck; Jenny C Chang; Gordon B Mills; Ching C Lau; Powel H Brown Journal: Clin Cancer Res Date: 2014-09-10 Impact factor: 12.531
Authors: Carol Sheridan; Hiromitsu Kishimoto; Robyn K Fuchs; Sanjana Mehrotra; Poornima Bhat-Nakshatri; Charles H Turner; Robert Goulet; Sunil Badve; Harikrishna Nakshatri Journal: Breast Cancer Res Date: 2006 Impact factor: 6.466
Authors: Noha Gwili; Stacey J Jones; Waleed Al Amri; Ian M Carr; Sarah Harris; Brian V Hogan; William E Hughes; Baek Kim; Fiona E Langlands; Rebecca A Millican-Slater; Arindam Pramanik; James L Thorne; Eldo T Verghese; Geoff Wells; Mervat Hamza; Layla Younis; Nevine M F El Deeb; Thomas A Hughes Journal: Br J Cancer Date: 2021-07-12 Impact factor: 7.640